Navigation Links
Medicago initiates work on Swine Flu strain
Date:4/28/2009

p>

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release


'/>"/>
SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
3. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
4. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
5. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
6. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
7. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
8. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
9. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
10. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
11. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... results for the six months ended June 30, ... Canadian dollars and presented under International Financial Reporting ... , Announced top-line results related to ... for subjects enrolled in the Phase 2 iDEAL ...
(Date:8/29/2014)... 29, 2014 A major challenge before ... start-up dense realm of Boston-Cambridge, is gaining visibility that ... James Sherley, the Director of Boston’s Adult Stem Cell ... and national visibility of his company an important priority ... In addition to a social media marketing campaign ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., the ... alcohol-based hand sanitizer, asks food processors and food handling ... hand sanitizer they’re currently using to Best Sanitizers’ ... is critical to fighting cross-contamination and the spread of ... believes there are key criteria that make a hand ...
(Date:8/28/2014)... , Aug. 28, 2014 ... a new market research report ... Whole Exome Sequencing ... (Library Preparation, Target Enrichment), by ... by Synthesis), by Application (Cancer, ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13
... Data Reported by Roche at 69th Scientific Sessions , ... Inc. (Nasdaq: VIAP ), a biotechnology company ... of cardiovascular and metabolic disease, announced today that preclinical ... inhibitors will be presented in a poster presentation at ...
... , Thursday, June 11th, 10:00 a.m. EDT , , ... ) announced today that the Company President and Chief Executive Officer, ... on Thursday, June 11th, 2009 at 10:00 a.m. EDT, to report ... a quarterly update of the Company. , , This call ...
... initial steps towards producing Influenza A (H1N1) VLP vaccine for ... 4 Novavax, Inc. (Nasdaq: NVAX ) and ... National Institute of Allergy and Infectious Diseases (NIAID), National Institutes ... the evaluation of a virus-like particle (VLP) vaccine candidate against ...
Cached Biology Technology:VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 2VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 4Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results 2Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results 3Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 2Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 3Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 4
(Date:8/28/2014)... DURHAM, N.C. -- Scientists have identified the developmental on-off ... microbes that produce more than two-thirds of the world,s ... would be to see whether it is possible to ... efficient. , The study, appearing August 28 in ... a small molecule called cyclic-di-GMP and a larger protein ...
(Date:8/28/2014)... compounds that could positively impact the global ... possible, thanks to researchers in Penn State,s ... suppository made from the seaweed-derived food ingredient ... Tenofovir provides a woman-initiated, drug-delivery vehicle that ... transmitted infections during unprotected heterosexual intercourse, the ...
(Date:8/28/2014)... Energy production systems are good examples of complex ... like a networkincluding water for cooling, transport to ... management. Every step in the network chain is ... all mutually dependent. A team of UK-based scientists ... previously explored. The findings have been published in ...
Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Inter-dependent networks stress test 2
... An increasing number of countries and regions are transitioning ... point for the world as a whole, according to ... cover. , The novel approach looks beyond simply how ... and considers the volume of timber, biomass, and captured ...
... body's mast cells are mainly associated with allergic reaction ... substances. However, researchers at Karolinska Institutet have now demonstrated ... like psoriasis and cancer. , Mast cells are most ... act like microscopic "bombs" to trigger the release of ...
... how taking the brakes off a "detox" gene causes chemotherapy ... Products made by a gene called NRF2 normally protect cells ... absorbing the materials and pumping them out of the cell. ... cleansing process. But lung cancer cells sabotage the expression ...
Cached Biology News:End of deforestation in view? Experts advance new way to size up global forest resources 2End of deforestation in view? Experts advance new way to size up global forest resources 3End of deforestation in view? Experts advance new way to size up global forest resources 4End of deforestation in view? Experts advance new way to size up global forest resources 5End of deforestation in view? Experts advance new way to size up global forest resources 6'Allergy cells' can aggravate cancer and psoriasis 2Key to lung cancer chemo resistance revealed 2
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Anti-gamma Glutamyl Transferase (gammaGT) Host: mouse monoclonal Species Reactivity: human Applications: WB, IP, FC Storage: 4C...
Biology Products: